A Platform Built to Scale.
A Pipeline Designed to Deliver.
With two lead programs discovered internally using the Soley platform advancing toward the clinic, alongside a growing set of de-risked preclinical assets, Soley’s differentiated platform serves as the engine for continuous, efficient drug discovery across complex diseases.
A Pipeline of First-in-Class Programs
Internally discovered.
Mechanistically differentiated.
Clinically directed.
In under three years, our platform has produced more than a dozen proprietary chemical series and numerous drug-like compounds. All medicines that we advance are discovered in-house, and are novel, patentable and have first-in-class mechanisms of action.
Anticancer Programs
SOL-001 Oncology
SOL-002 Oncology
SOL-003 Oncology
SOL-004, -005, -006 Oncology
SOL-007 Oncology
SOL-008 Oncology
Research
Discovery
Lead Selection
Lead Optimization
IND-enabling Studies
Disease Reversal Programs
– Stress Reducing
Stress Reversal Neurodegenerative
Disease
Disease
Stress Reversal Obesity /
Metabolic Diseases
Metabolic Diseases
Stress Reversal Hair Regeneration
Oncology: Lead Programs
Oncology is the first focus area for Soley’s platform, with two lead assets advancing toward Phase 1 trials. Our first development candidates are oral small molecules targeting novel, previously undruggable mechanisms. They have demonstrated strong preclinical efficacy in both hematologic and solid tumors and non-cytotoxicity against non-cancer cells.
Beyond Oncology
Soley is advancing discovery programs in neurodegeneration, obesity / metabolic disease, and hair regeneration. Each program is driven by distinctive cell sensing and stress-response with strong in vitro and in vivo translation. These programs aim to discover molecules that reverse cellular disease state to a healthy and more functional state.
See the Science Behind the Medicines
Decades of cross-disciplinary research and platform development drive Soley’s platform and pipeline.